Exact Sciences may have had disappointing Q3 earnings, but its liquidity cushions and new product approval indicate strong ...

Exact Sciences (EXAS) will present three abstracts highlighting significant advancements in the development of a multi-cancer early detection test. The results of a study evaluating a new ...

Wisconsin-based Exact Sciences Corp. is a molecular diagnostics company, which focuses on the early detection and prevention of colorectal cancer. Read More on EXAS: EXACT Sciences NewsMORE ...

Study finds mosaicism in Down syndrome reduces Alzheimer's risk, providing new insights into genetic influences on cognitive ...

These updates account for the growing use of genetic testing in cancer prevention, screening, and treatment. These expanded guidelines reflect the recommendations from leading experts on genetic ...

The Pokemon TCG Pocket Genetic Apex Emblem event is a limited-time event in which players can win special emblems for their profile by beating other players in battles. To participate in the event ...

Now, the model has simulated every Week 10 game 10,000 times. You can only see the model's Week 10 NFL exact score predictions at SportsLine. After diving into every game on the Week 10 NFL ...

Before you make any Week 10 NFL picks, be sure to see the exact NFL score predictions from SportsLine expert Eric Cohen. Cohen, a SportsLine NFL expert and host of the Friday "Early Edge NFL ...

Exact Sciences' Q3 earnings report has led to a ~25% drop in its share price, due to a slight guidance cut and narrow revenue miss. Despite impressive historic revenue growth, Exact faces ...

Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook. CEO Kevin Conroy said the ...

This journal utilises an Online Peer Review Service (OPRS) for submissions. By clicking "Continue" you will be taken to our partner site https://mc.manuscriptcentral ...

Exact Sciences Exact Sciences shares plunged Wednesday after the company reported widening losses. The maker of the Cologuard colon cancer screening test lowered its full-year outlook.